Jazz Pharma Plc (NASDAQ:JAZZ).
Baird Financial Group, Inc. decreased its ownership in Jazz Pharma Plc stock by 5.0% as of the end of the last quarter. Its position was valued at $26,956,000 a decrease of $3,206,000 according to the filing.
These firms have modified their investment in JAZZ. Tredje Ap-fonden downsized its investment by shedding 110 shares a decrease of 3.4% in the quarter. Tredje Ap-fonden now holds 3,140 shares with a value of $459,000. The value of the position overall is down by 9.1%. Raymond James & Associates bolstered its position by buying 400 shares an increase of 3.3% as of 09/30/2017. Raymond James & Associates currently owns 12,500 shares valued at $48,000. The total value of its holdings decreased 44.2%.
Dimensional Fund Advisors Lp augmented its holdings by buying 17,272 shares an increase of 7.5% from 06/30/2017 to 09/30/2017. Dimensional Fund Advisors Lp owns 247,170 shares worth $36,151,000. The value of the position overall is up by 1.1%.
November 10 investment analysts at HC Wainwright maintained a company rating of “Neutral” targeting a price of $150.00. On November 8 Wells Fargo & Company kept the company rating at “Outperform” with a current price target of $172.00.
Equity analyst Royal Bank Of Canada lowered the price target on November 8 changing the forecast from $210.00 to $195.00 and issued a “Outperform” rating. October 26 investment analysts at Stifel Nicolaus made no change to the stock rating of “Buy” projecting a price of $190.00.
On October 23 analysts at Cowen and Company updated guidance on JAZZ and giving a rating of “Buy” and projecting a price target of $190.00. Equity analyst Piper Jaffray Companies released a research note on JAZZ stating a rating of “Buy” and a price target of $177.00.
The company is so far trading down since yesterday’s close of 134.24. The most current P/E ratio is 21.98 and market capitalization is 8.05B. In the latest earnings report the EPS was $6.07 with 59.95M shares presently outstanding.
Short traders are feeling a little more bullish on Jazz Pharma Plc of late looking at the decrease in short interest. The stock experienced a fall in short interest of -3.02% as of the latest report on October 13, 2017. Short shares decreased from 2,699,734 to 2,618,073 over that timeframe. The days to cover decreased to 7.0 and the percentage of shorted shares is 0.04% as of October 13.